GlassScriptPhysician profile
Natasha N Hardeman
NPI 1104869148
$3,618.36
in general payments reported to CMS, 2019-2025
26 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $359 · 2021: $810 · 2022: $588 · 2023: $461 · 2024: $357 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.37 | 2019-2025 | |
| Pfizer INC. | $462.81 | 2019-2025 | |
| Exeltis, USA INC. | $403.73 | 2020-2025 | Slynd |
| Astellas Pharma US INC | $342.48 | 2023-2025 | Veozah |
| Organon LLC | $301.59 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $188.37 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Mayne Pharma Commercial LLC | $127.29 | 2022-2025 | |
| Medtronic, INC. | $101.20 | 2023 | Sonicision |
| Channel Medsystems, INC. | $68.58 | 2025 | |
| Merck Sharp & Dohme LLC | $64.63 | 2020-2023 | Gardasil 9 |
| Agile Therapeutics, INC. | $60.36 | 2021-2023 | Twirla |
| Allergan, INC. | $41.14 | 2019 | |
| Evofem Biosciences, INC. | $35.97 | 2021-2025 | Solosec, Phexx, Phexxi |
| Baxter Healthcare | $28.84 | 2020 | |
| Becton, Dickinson and Company | $28.49 | 2023 | Bd Onclarity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.17 | 2021-2022 | |
| Sage Therapeutics, LLC | $20.43 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $20.43 | 2025 | Qelbree |
| Amgen INC. | $17.91 | 2020 | |
| Therapeuticsmd, INC. | $17.43 | 2020 | |
| Sumitomo Pharma America, INC. | $17.30 | 2025 | Gemtesa |
| Minerva Surgical, INC | $15.52 | 2024 | |
| Smith+Nephew, INC. | $15.16 | 2023 | Acticoat 4" X 4", Pico 7 |
| Scynexis, INC. | $13.63 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $12.40 | 2019 | |
| Coopersurgical, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Hardeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.